Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum subsp. infantis BI45
- Development stage
- Preclinical
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum subsp. infantis BI45 is a specific probiotic strain of the species Bifidobacterium longum subsp. infantis, which is a Gram-positive, anaerobic, heterofermentative bacterium. This subspecies is recognized for its unique ability to metabolize the full spectrum of human milk oligosaccharides (HMOs), enabling superior colonization in the infant gut and facilitating the formation of a bifidobacteria-rich microbiota. Probiotics containing B. infantis have demonstrated anti-inflammatory activity, reduction of intestinal permeability, and positive modulation of immune responses, with clinical studies supporting their use to enhance intestinal and immune functions in both infants and adults. Specifically, the BI45 strain is being studied as a food supplement for its potential to improve intestinal and immune functions in healthy adults[1][4].
- Other names
- bifidobacterium longum subsp. infantis BI45
Beyond the preview
Go deeper on bifidobacterium longum subsp. infantis BI45.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum subsp. infantis BI45.